A synthetic 51-residue peptide decoy targeting the Human Rhinovirus VP1 canyon achieved 92% interface efficiency in simulations, providing a variant-proof shield against viral entry.
A novel synthetic peptide decoy shows high interface efficiency in simulations, suggesting potential as a topical prophylactic against Human Rhinovirus.
Absolute Event Rate: 0% vs 0%
Human Rhinovirus (HRV) remains a pervasive global health challenge due to the high genetic diversity of its 160+ known serotypes, rendering traditional vaccine approaches ineffective. This paper presents a novel prophylactic strategy utilizing a synthetic peptide decoy designed to target the highly conserved "canyon" region of the viral VP1 protein. By identifying a rigid structural floor (mean B-factor 13.46) within the ICAM-1 binding site, a 51-residue high-tension decoy was engineered with optimized electrostatic and hydrophobic complementarity (-0.32 Kyte-Doolittle score). Simulation data indicates a 92% interface efficiency, suggesting that a topical mechanical barrier can provide a robust, variant-proof shield against viral entry. This approach shifts the paradigm from systemic pharmaceutical intervention to localized, structural interface management.
Matthew Sykes (Thu,) reported a other. A synthetic 51-residue peptide decoy targeting the Human Rhinovirus VP1 canyon achieved 92% interface efficiency in simulations, providing a variant-proof shield against viral entry.